Antibody production ideally starts in laboratory where different research studies, according to disease the research is performed. Based on the research further the production process is done according to process steps like upstream processing or downstream processing among others. The production process further have different clinical studies to check the effectiveness of the antibody produce and its benefits as well as side effects on patients. The growing burden of different disease in Asia Pacific region has propel the demand for the market across the region. The market in Asia Pacific region is anticipated to witness the growth at highest pace during the estimated time period.
The Asia Pacific market is driven by increasing burden of different disease and Increasing Adoption of Targeted Immunotherapy which has led the new growth demand for market in the region. The features like rising incidence of different cancer types has led the demand for potential medication thereby antibody production has increasing demand in the Asia Pacific market. Besides, increasing r&d expenditure in pharmaceutical and biotechnological companies and rising number of fast track and orphan drug designations is contributing to hug extent for the growth of Asia Pacific region market.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Asia Pacific antibody production market. In addition, complete analysis of changes on the Asia Pacific antibody production market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. COVID-19 had a positive impact on market as the demand for the production of new antibody was accelerated specifically for corona viruses.
The antibody production market comprises of different market segment like process, end user, class and country.
The antibody production includes key process segment of upstream processing, downstream processing, ion exchange (iex) chromatography resins, hydrophobic interaction chromatography (hic) resins, multimodal chromatography resins, and filtration. Further, upstream processing includes bioreactors and consumables. Bioreactors is further sub segmented to large-scale bioreactors and single-use bioreactors (subs). Likewise, consumables includes media and reagents and buffers. Also, downstream processing is bifurcated to chromatography instruments and chromatography resins. Additionally filtration includes filtration systems and filtration consumables and accessories. The downstream processing is expected to dominate in the market witnessing the growth at highest pace during the estimated time period. The rising investment in antibody production using downstream processing provides number of benefits at different operation stages. Besides rising R&D for downstream processing is expected to drive the growth of region in market. Furthermore, upstream processing is excepted to witness new growth avenue due to rising adoption of single use upstream bioprocessing, rising demand for different antibody in market is driving the growth of segment.
The antibody production market finds its end use in pharmaceutical and biotechnology companies, diagnostic laboratories and research institutes. Pharmaceutical and biotechnology companies is expected to gain major market for the antibody production in Asia Pacific. The enormous presence of major company’s manufacturer in region and different countries has led the new growth avenue for market as well as the segment. The growing demand for different antibody products specifically for disease like cancer has propel the growth of segment. Besides, research institutes is likely to contribute healthily growth in the market.
The antibody production by class is available in market according to monoclonal antibodies, murine, chimeric, humanized and polyclonal antibodies. Monoclonal antibodies is increasingly witnessing emerging demand for antibody production due to rise in incidence of cancer and other disease. Besides, approval for different antibody production is expected to propel the growth of segment. Likewise, increasing government focus towards improving the patient care and reduce burden of different disease is the key factor accelerating the growth of the segment. In addition, polyclonal antibodies followed by murine, chimeric, and humanized is expected to witness the growth at moderate pace during projection time period.
Asia Pacific antibody production market is studied for the following countries like China, India, Japan and Rest of APAC among others. In Asia Pacific market, China is expected to lead for the antibody production owing to increasing awareness for antibody like monoclonal antibodies. Besides, demand for cost effective antibodies has propel the demand for the market. Likewise, increasing cases of infectious disease and burden of different disease like cancer has boosted the demand for the market. This market features is expected to fuel the demand for market during the forecast period. In addition, India is likely to witness rapid growth during estimated time period. The rising innovation and research studies for antibody production is expected to drive the market growth.
The key players in antibody production market are GE Healthcare (General Electric Company), Merck KGAA, Thermo Fisher Scientific, Inc., Sartorius AG, Pall Corporation (Danaher Corporation), Sigma-Aldrich Corporation (Merck KGAA), Eppendorf AG, Cellab GmbH, Integra Biosciences AG and Fibercell Systems Inc. among others.
June 2021: Chugai Pharmaceutical Ltd. had announced that the company has filed a new drug application with the Ministry of Health, Labor and Welfare for the antibody cocktail casirivimab and imdevimab for the treatment of COVID-19. The application seeks the special approval for emergency.
May 2021: Roche India had announced that Central Drugs Standards Control Organization has provided the emergency use authorisation for Roche’s antibody cocktail (Casirivimab and Imdevimab) in India. The emergency use authorization will now enable Roche Company to import the global manufactured products batches to India. It will be marketed and distributed in India with strategic partnership with Cipla Limited.
April 2021: Harbour BioMed had presented a newly discovered fully human anti- B7H7 monoclonal antibody at American Association for Cancer Research. The anti- B7H7 monoclonal is a novel immune oncology antibody with potent anti-tumor activity generated using HBM proprietary H2L2 Harbour Mice platform.
October 2020: IAVI and Serum Institute of India had announced an agreement with Merck KGaA, Germany to develop SARS CoV-2 neutralizing monoclonal antibodies (mAbs) and is co- invented by IAVI and Scripps Research as innovative interventions for COVID-19 pandemic.
The report analyses the Asia Pacific antibody production market based on by process, end user, class and country. The antibody production includes key process segment of upstream processing, downstream processing, ion exchange (iex) chromatography resins, hydrophobic interaction chromatography (hic) resins, multimodal chromatography resins, and filtration. The antibody production market finds its end use in pharmaceutical and biotechnology companies, diagnostic laboratories and research institutes. The antibody production by class is available in market according to monoclonal antibodies, murine, chimeric, humanized and polyclonal antibodies. Asia Pacific antibody production market is studied for the following countries like China, India, Japan and Rest of APAC among others.
Why to buy this report: